Spots Global Cancer Trial Database for Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
Official Title: A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months)Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy
Study ID: NCT00888810
Study Description
Brief Summary: The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Centre François Baclesse, Caen, Calvados, France
Centre Paul Papin, Angers, , France
CHU Jean MINJOZ, Besancon, , France
Institut Bergonié, Bordeaux, , France
Centre G-F Leclerc, Dijon, , France
CHD Les Oudairies, La ROCHE SUR YON, , France
Centre Jean Bernard, Le MANS, , France
Centre Val d'Aurelle, Montpellier, , France
Centre azuréen de cancérologie, Mougins, , France
Centre Alexis vautrin, Nancy, , France
Centre Catherine de Sienne, Nantes, , France
Centre René Gauducheau, Nantes, , France
Centre Antoine Lacassagne, Nice, , France
Hôpital Diaconesses, Paris, , France
Institut CURIE, Paris, , France
APHP Hopital TENON, Paris, , France
Institut Jean Godinot, Reims, , France
Institut de Cancérologie de la Loire, Saint Etienne, , France
Centre Paul Strauss, Strasbourg, , France
Institut Claudius regaud, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Name: Florence JOLY, MD-PHD
Affiliation: Centre François Baclesse
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
